Benchmark International advises RX30 on strategic equity investment, representing one of Benchmark’s largest deals in 2015.
Strategic Investment in Leading Developer of Pharmacy Management Software
Benchmark International’s Major Transaction Team had the opportunity to represent Transaction Data Systems, Inc., doing business as Rx30 (“Rx30”), in a transaction with new investor GTCR completed on Monday. GTCR’s strategic equity investment in Rx30 will accelerate Rx30’s new product development and continued growth. Rx30’s CEO, Steve Wubker, and the existing management team will continue to lead the company.
Rx30 is a leading national developer and supplier of vertical enterprise software that offers pharmacy management software solutions to the independent, hospital, long-term care and specialty pharmacy markets. Dedicated to the independent pharmacy market for the last 35 years, Rx30 offers a suite of market-leading software solutions to enable prescription filling, pharmacy management and other critical functions for its pharmacist customers.
Kendall Stafford, Managing Director of Benchmark International, stated, “It was a pleasure to advise Rx30 on this transaction. It was important for CEO Steve Wubker and the existing management team to partner with an equity investor that would add both healthcare and technology expertise to help accelerate the growth of the company. GTCR was the perfect fit. The transaction allowed the founding shareholders to exit happily at close, knowing their company is in good hands, with the existing management team continuing to grow the business and a new equity partnership in place to support their vision. It will be an exciting road forward for Rx30 and we were fortunate to be a part of the company’s growth and starting this next chapter. We wish each party the best of luck.”
If you are considering a strategic partnership or exit, Benchmark International should be your first call.
Contact Benchmark’s International Major Transactions Team:
+1 813 898 2350
+44 (0) 161 359 4400